Swine Epidemic Diarrhea Vaccines Market

The swine epidemic diarrhea vaccines market was valued at USD 428.3 Mn by 2019. Growing incidence of porcine epidemic diarrhea virus infection among the swine population worldwide drives the swine epidemic diarrhea vaccines market growth.

Swine epidemic diarrhea vaccines were first reported in 2013 in the United States killing over 100,000 piglets causing huge economic loss, further the infection spread to Canada, Mexico, China, South Korea, etc. In the present scenario there are very few companies providing PEDV vaccines which provides a huge opportunity for other biopharmaceutical companies to enter the market in the near future.

The major segments related to the swine epidemic diarrhea vaccines market are: 

By Type (2017–2027; US$ Mn)

Live Vaccines

Killed Vaccines

By Application (2017–2027; US$ Mn)

Neonatal Vaccines

Adult Vaccines

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global swine epidemic diarrhea vaccines market
• The overall segmentation of the swine epidemic diarrhea vaccines market, by type, application, and geography is minutely studied. Live vaccines and neonatal pigs are dominating the type and application segments respectively
• A constant increase in the spread of porcine epidemic diarrhea virus (PEDV) across pig farms worldwide
• Presence of few players in the PEDV vaccines market creates a lucrative opportunity for other veterinary vaccines manufacturers to enter the PEDV vaccines market

Report gist?

• The study of the global swine epidemic diarrhea vaccines market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers a qualitative and quantitative analysis of the overall market segmented on the basis of type and application and categorization of the same at geography level
• This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning 

Significant customers?

• This study is suitable for industry participants and stakeholders in the biopharmaceutical manufacturers actively engaged in the production and marketing of swine epidemic diarrhea vaccines due to the growing incidence of porcine epidemic diarrhea virus (PEDV) infection among swine population worldwide
• The report will benefit researchers engaged in the development of swine epidemic diarrhea vaccines to curb the mortality rate associated with PEVD virus infection occurring in pig farms throughout the globe
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to swine epidemic diarrhea vaccines market
• Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Killed vaccines are dominating the type segment for swine epidemic diarrhea vaccines market. The killed vaccines are useful in prefarrowing vaccination of the healthy pregnant sows and gilts against the diarrheal disease occurring in the neonatal pigs. The vaccine also has an adjuvant which helps in improving the immune response. Live vaccines are anticipated to register marvelous market growth in the near future on account of the increasing research activities conducting in several biopharmaceutical companies to create a live attenuated vaccine delivered via oral route to protect the neonatal pigs form the highly virulent PEDV infection.

Neonatal pigs are currently spearheading the application segment for swine epidemic diarrhea vaccines market. As per the clinical studies provided by the Korean Vaccine Society (KCS) have further elucidated the findings that approximately 80% of the mortality rate associated with porcine epidemic diarrhea virus infection takes place I the neonatal pigs. The viral strain which was associated with this huge mortality rate in the neonatal pigs was identified as CV777, belonging to the Alphacoronavirus genus. Adult pigs are anticipated to register sturdy market growth during the forecast period on account of the increasing incidence of PEDv Type I infection in the adult pigs. The virus causes the damage of the microvilli surface of the pig gut thereby reducing the absorptive surface which causes diarrhea and dehydration which usually results in the death of herds of pigs on a pig farm causing huge economic loss to the farmers and breeders worldwide.

North America is presently leading the geography segment for swine epidemic diarrhea vaccines market. A significant increase in the spread of porcine epidemic diarrhea virus infection in pig farms primarily drives the market growth in the region. Increasing demand for pork meat further accentuates the swine epidemic diarrhea vaccines market. The supportive regulatory environment provided by the USFDA for the early clearance of vaccines used for the treatment of PEDV viral infection among the population will further propel the market growth in the region. Europe is considered as the second-largest regional segment due to the increased funding provided by the government to the academic research institutes to develop vaccines to curb the mortality rate associated with porcine epidemic diarrhea vaccines market. The Asia Pacific is anticipated to register the fastest market growth in the regional segment for swine epidemic diarrhea vaccines market. Significant growth in the meat processing industry and increasing awareness of the PEVD infection among farmers determine the market growth in the Asia Pacific region.